Publications by authors named "V Katalinic Jankovic"
Article Synopsis
- Researchers have developed approximate methods to study exciton transport in molecular aggregates influenced by structured environments, moving beyond basic models that often become complex and hard to manage.
- They introduced a self-consistent Born approximation to better accommodate exciton-environment interactions and improve calculations of energy transfer dynamics in these systems.
- Their findings indicate that this new approach aligns well with more comprehensive models across various conditions, suggesting it effectively describes exciton behavior even in complex scenarios like the Fenna-Matthews-Olson complex.
Purpose: Preclinical data indicate that fianlimab (antilymphocyte activation gene-3) plus cemiplimab (anti-PD-1) enhances antitumor activity. Here, we report prespecified final analyses of the dose-escalation part of a first-in-human, phase 1 study (NCT03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies.
Patients And Methods: Adult patients received 1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks (Q3W) across various dose-escalation schedules.
Species belonging to the complex (MKC) are frequently isolated from humans and the environment and can cause serious diseases. The most common MKC infections are caused by the species (), leading to tuberculosis-like disease. However, a broad spectrum of virulence, antimicrobial resistance and pathogenicity of these non-tuberculous mycobacteria (NTM) are observed across the MKC.
View Article and Find Full Text PDFPurpose: Coblockade of lymphocyte activation gene-3 (LAG-3) and PD-1 receptors could provide significant clinical benefit for patients with advanced melanoma. Fianlimab and cemiplimab are high-affinity, human, hinge-stabilized IgG4 monoclonal antibodies, targeting LAG-3 and PD-1, respectively. We report results from a first-in-human phase-I study of fianlimab and cemiplimab safety and efficacy in various malignancies including advanced melanoma.
View Article and Find Full Text PDFMolecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
J Immunother Cancer
March 2024
Article Synopsis
- Odronextamab is a targeted therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) that works by engaging T-cells to attack cancer cells, showing promising results in a Phase I study with manageable safety.
- The study involved weekly intravenous dosing and analyzed patient tumor biopsies to identify biomarkers and resistance mechanisms, finding high baseline CD20 expression in most cases but variable levels in other related antigens.
- Results suggested that higher levels of tumor programmed cell death-ligand 1 and specific immune cell types may correlate with better responses to treatment, while mutations leading to loss of CD20 expression may contribute to resistance.